November 2025
1. GOGEBAKAN KC, Elsisi Z, Montano-Campos F, Owens L, et al
   Prostate-specific membrane antigen positron emission tomography/computed tomography imaging as a precision diagnostic at prostate cancer recurrence after radical prostatectomy: Modeling long-term survival.
   Cancer. 2025;131:e70131.
   

   >> Share

   
   October 2025
2. ROVIELLO G, Catalano M, Antonuzzo L
   From treatment escalation to ultra de-intensification: When androgen-deprivation therapy alone remains a rational choice in metastatic hormone-sensitive prostate cancer.
   Cancer. 2025;131:e70117.
   

   >> Share

   
   
3. TSUNG I, Reichert ZR, Ramalingam SS
   Reply to "From treatment escalation to ultra de-intensification: When androgen-deprivation therapy alone remains a rational choice in metastatic hormone-sensitive prostate cancer".
   Cancer. 2025;131:e70119.
   

   >> Share

   
   
4. 
   Erratum to "Consensus-built recommendations to improve prostate cancer outcomes: A summary of the American Cancer Society Prostate Cancer Collaborative".
   Cancer. 2025;131:e70105.
   

   >> Share

   
   September 2025
5. NGUYEN DD, Satkunasivam R, Aminoltejari K, Hird A, et al
   Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: A population-based study.
   Cancer. 2025;131:e70070.
   

   >> Share

   
   
6. NIERENGARTEN MB
   Outcomes show a reduction in treatment failure associated with dose-escalated, hypofractionated radiation therapy for localized prostate cancer.
   Cancer. 2025;131:e70013.
   

   >> Share

   
   
7. NIERENGARTEN MB
   A persistent PSA level following radical prostatectomy for prostate cancer is associated with a worse prognosis.
   Cancer. 2025;131:e70012.
   

   >> Share

   
   August 2025
8. TSUNG I, Yentz SE, Reichert ZR
   Controversies in metastatic hormone-sensitive prostate cancer.
   Cancer. 2025;131:e70030.
   

   >> Share

   
   
9. NORIEGA ESQUIVES BS, Manoharan A, Penedo FJ, Dee EC, et al
   Factors associated with prostate cancer screening among Hispanic men: Results from the Hispanic Community Health Study/Study of Latinos.
   Cancer. 2025;131:e70029.
   

   >> Share

   
   
10. SANDERS J, Levell C, Brand LJ, Dahut WL, et al
    Consensus-built recommendations to improve prostate cancer outcomes: A summary of the American Cancer Society Prostate Cancer Collaborative.
    Cancer. 2025;131:e70010.
    

    >> Share

    
    
11. SAEED F, Berchuck JE, Bilen MA, Gandhi JS, et al
    Optimizing treatment for metastatic castration-resistant prostate cancer: Food and Drug Administration-approved therapies, emerging strategies, and biomarker-driven approaches.
    Cancer. 2025;131:e70037.
    

    >> Share

    
    
12. FALAGARIO UG, Pellegrino F, Abbadi A, Bjornebo L, et al
    Detectable prostate-specific antigen after radiotherapy for clinically localized prostate cancer.
    Cancer. 2025;131:e70045.
    

    >> Share

    
    
13. GREEN-LOTT AY, Wadhwa A, Bailey AV, Kwan L, et al
    Prostate cancer incidence and outcomes among Vietnam veterans receiving care in the Veterans Health Administration.
    Cancer. 2025;131:e70007.
    

    >> Share

    
    
14. NIERENGARTEN MB
    Superior prostate cancer detection with LATP versus TRUS.
    Cancer. 2025;131:e35958.
    

    >> Share

    
    July 2025
15. GRANT RS, Kakani P, Movva P, Daskivich TJ, et al
    Identifying cribriform and intraductal histology on magnetic resonance imaging-assisted biopsy for patients with intermediate-grade prostate cancer: Implications for active surveillance.
    Cancer. 2025;131:e35968.
    

    >> Share

    
    June 2025
16. NIERENGARTEN MB
    Acute toxicity of prostate cancer radiotherapy associated with late toxicity: Acute toxicity following prostate cancer radiotherapy was statistically and significantly associated with late toxicity in patient-reported quality-of-life metrics.
    Cancer. 2025;131:e35886.
    

    >> Share

    
    
17. GINSBURG KB, Sessine MS, Bock CH, Goodman M, et al
    Factors associated with switching from active surveillance to treatment in men with low-risk prostate cancer: A population-based study.
    Cancer. 2025;131:e35909.
    

    >> Share

    
    May 2025
18. GARG SK, Kohli K, Garg IK, Garg YK, et al
    Disparities in receipt of palliative-intent treatment among disaggregated Hispanic populations with breast, lung, and prostate cancer in the United States.
    Cancer. 2025;131:e35903.
    

    >> Share

    
    April 2025
19. LAWRENCE WR, Freedman ND, McGee-Avila JK, Hong HG, et al
    Contemporary neighborhood redlining and racial mortgage lending bias and disparities in prostate cancer survival.
    Cancer. 2025;131:e35850.
    

    >> Share

    
    
20. FUKUOKAYA W, Mori K, Yanagisawa T, Urabe F, et al
    Tumor burden and heterogenous treatment effect of apalutamide in metastatic castration-sensitive prostate cancer.
    Cancer. 2025;131:e35819.
    

    >> Share

    
    March 2025
21. SEBASTIAN NT, Patil D, Patel PR, Jani AB, et al
    Utilization, health care expenditures, and patient costs of definitive treatment modalities for localized prostate cancer in the United States.
    Cancer. 2025;131:e35795.
    

    >> Share

    
    
22. NIERENGARTEN MB
    Higher rates of long-term complications after prostate cancer treatment.
    Cancer. 2025;131:e35761.
    

    >> Share

    
    
23. NIERENGARTEN MB
    Reduced long-term side effects with MRI-guided radiotherapy in prostate cancer.
    Cancer. 2025;131:e35762.
    

    >> Share

    
    February 2025
24. NIERENGARTEN MB
    Healthy diet may reduce the risk of low-grade prostate cancer progressing to a higher grade.
    Cancer. 2025;131:e35740.
    

    >> Share

    
    January 2025
25. CASTANEDA P, Kuhlmann PK, Ithisuphalap J, Howard LE, et al
    Alternate definitions of adverse pathology to predict a very high risk of metastasis in men with intermediate- and low-risk prostate cancer.
    Cancer. 2025;131:e35684.
    

    >> Share

    
    
26. NORIEGA ESQUIVES BS, Moreno PI, Munoz E, Lad TE, et al
    Effects of a culturally tailored patient navigation program on unmet supportive care needs in Hispanic/Latino cancer survivors: A randomized controlled trial.
    Cancer. 2025;131:e35626.
    

    >> Share

    
    December 2024
27. MUKAND NH, Chirikova E, Lichtensztajn D, Negoita S, et al
    Assessing sociodemographic and regional disparities in Oncotype DX Genomic Prostate Score uptake.
    Cancer. 2024;130:4298-4305.
    

    >> Share

    
    
28. SAYAN M, Chen MH, Wu J, Leeman JE, et al
    Biochemical response to neoadjuvant androgen deprivation therapy before radiation therapy and the risk of death in patients with unfavorable-risk prostate cancer: A secondary analysis of a randomized clinical trial.
    Cancer. 2024 Dec 4. doi: 10.1002/cncr.35674.
    

    >> Share

    
    
29. BRYCE AH, Agarwal N, Beltran H, Hussain MH, et al
    Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024.
    Cancer. 2024 Dec 1. doi: 10.1002/cncr.35612.
    

    >> Share

    
    November 2024
30. SRIVASTAVA A, Liu X, Maganty A, Kaufman SR, et al
    Commercial prices and their influence on urology practices: Prostate cancer care among men with Medicare.
    Cancer. 2024 Nov 5. doi: 10.1002/cncr.35633.
    

    >> Share

    
    
31. SOERENSEN SJC, Lim DS, Montez-Rath ME, Chertow GM, et al
    Pesticides and prostate cancer incidence and mortality: An environment-wide association study.
    Cancer. 2024 Nov 4. doi: 10.1002/cncr.35572.
    

    >> Share

    
    October 2024
32. NIERENGARTEN MB
    Androgen receptor signaling inhibitors linked to increased risk of cardiovascular adverse events in prostate cancer.
    Cancer. 2024;130:3399.
    

    >> Share

    
    
33. MOUSA A, Nguyen DD, Lalani AK, Satkunasivam R, et al
    Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen-deprivation therapy: A population-based assessment of adherence to therapeutic monitoring guidelines.
    Cancer. 2024 Oct 13. doi: 10.1002/cncr.35606.
    

    >> Share

    
    
34. CIRULLI GO, Davis M, Stephens A, Chiarelli G, et al
    Midlife baseline prostate-specific antigen, velocity, and doubling time association with lethal prostate cancer and mortality.
    Cancer. 2024 Oct 8. doi: 10.1002/cncr.35563.
    

    >> Share

    
    September 2024
35. ZHENG R, Daniels JP, Moreira DM, Eslamimehr S, et al
    Does insulin resistance predict prostate cancer? Results from the Reduction by Dutasteride of Prostate Cancer (REDUCE) Trial.
    Cancer. 2024 Sep 27. doi: 10.1002/cncr.35568.
    

    >> Share

    
    
36. KILBRIDGE KL, Patil D, Filson CP, Shelton JW, et al
    Tailoring language for genitourinary function in patients with newly diagnosed prostate cancer to facilitate discussions in diverse populations and overcome health literacy barriers.
    Cancer. 2024 Sep 10. doi: 10.1002/cncr.35498.
    

    >> Share

    
    
37. 
    Addition of apalutamide to ADT after radical prostatectomy offers encouraging results.
    Cancer. 2024;130:2896.
    

    >> Share

    
    
38. NIERENGARTEN MB
    Optimal timing of radiotherapy after radical prostatectomy points to salvage radiotherapy for PSA failure.
    Cancer. 2024;130:2895.
    

    >> Share

    
    August 2024
39. BEATRICI E, Paciotti M, Nguyen DD, Filipas DK, et al
    Estimating the impact of enhanced care at minority-serving hospitals on disparities in the treatment of breast, prostate, lung, and colon cancers.
    Cancer. 2024;130:2770-2781.
    

    >> Share

    
    July 2024
40. MORGANS AK
    Optimizing assessments of quality of life in contemporary prostate cancer clinical trials.
    Cancer. 2024 Jul 27. doi: 10.1002/cncr.35485.
    

    >> Share

    
    
41. LEE YHA, Kai Chan JS, Leung CH, Liu AQ, et al
    Comparison of infection risk between enzalutamide and abiraterone in patients with prostate cancer.
    Cancer. 2024 Jul 21. doi: 10.1002/cncr.35472.
    

    >> Share

    
    
42. MEAGHER M, Morgan K, Deshler L, Riviere P, et al
    Prostate cancer in transgender women: A propensity score-matched analysis of disease severity and survival.
    Cancer. 2024 Jul 21. doi: 10.1002/cncr.35469.
    

    >> Share

    
    
43. SANYAL C, Ragavan MV
    Beyond the PSA: The hidden costs of screening in prostate cancer.
    Cancer. 2024 Jul 16. doi: 10.1002/cncr.35474.
    

    >> Share

    
    
44. NIERENGARTEN MB
    Novel hormone is safe and effective in men receiving radiotherapy for prostate cancer.
    Cancer. 2024;130:2408.
    

    >> Share

    
    
45. SRIVASTAVA A, Tilea A, Kim DD, Dalton VK, et al
    Out-of-pocket costs for diagnostic testing following abnormal prostate cancer screening among privately insured men.
    Cancer. 2024 Jul 15. doi: 10.1002/cncr.35392.
    

    >> Share

    
    
46. GONG J, Janes JL, Trustram Eve C, Stock S, et al
    Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancer.
    Cancer. 2024 Jul 1. doi: 10.1002/cncr.35466.
    

    >> Share

    
    June 2024
47. MORRIS MJ, de Bono J, Nagarajah J, Sartor O, et al
    Correlation analyses of radiographic progression-free survival with clinical and health-related quality of life outcomes in metastatic castration-resistant prostate cancer: Analysis of the phase 3 VISION trial.
    Cancer. 2024 Jun 21. doi: 10.1002/cncr.35438.
    

    >> Share

    
    
48. BASARIA S, Taplin ME, McDonnell M, Simonson DC, et al
    Insulin resistance during androgen deprivation therapy in men with prostate cancer.
    Cancer. 2024 Jun 16. doi: 10.1002/cncr.35443.
    

    >> Share

    
    
49. PAGADALA MS, Lui A, Lynch J, Karunamuni R, et al
    Healthy lifestyle and prostate cancer risk in the Million Veteran Program.
    Cancer. 2024 Jun 12. doi: 10.1002/cncr.35434.
    

    >> Share

    
    
50. LABBAN M, Stone BV, Steele GL, Salinas KE, et al
    A qualitative approach to understanding the drivers of unequal receipt of definitive therapy for Black men with prostate cancer in Massachusetts.
    Cancer. 2024 Jun 4. doi: 10.1002/cncr.35366.
    

    >> Share

    
    May 2024
51. TINSLEY SA, Finati M, Stephens A, Chiarelli G, et al
    Race has no impact on prostate cancer-specific mortality, when comparing patients with similar risk of other-cause mortality: An analysis of a population-based cohort.
    Cancer. 2024 May 28. doi: 10.1002/cncr.35386.
    

    >> Share

    
    April 2024
52. BENADADA F, Saad F, Delouya G, Taussky D, et al
    Charles Brenton Huggins: A historical review of the Nobel laureate's pioneering discoveries.
    Cancer. 2024;130:1019-1024.
    

    >> Share

    
    March 2024
53. SOLANKI AJ, Kamrava M, Posadas EM, Freedland SJ, et al
    A practical guide for assessing and managing cardiovascular risk during androgen-deprivation therapy in patients with prostate cancer.
    Cancer. 2024 Mar 26. doi: 10.1002/cncr.35285.
    

    >> Share

    
    
54. PEPPONE LJ, Kleckner AS, Fung C, Puzas JE, et al
    High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT.
    Cancer. 2024 Mar 23. doi: 10.1002/cncr.35275.
    

    >> Share

    
    
55. LIM FAT G, Alibhai S
    Effect of hormonal therapies for prostate cancer on cognition: The ongoing search for clarity.
    Cancer. 2024 Mar 16. doi: 10.1002/cncr.35283.
    

    >> Share

    
    
56. WALBURN T, Chen MH, Loffredo M, McMahon E, et al
    Secondary analysis of late major gastrointestinal and genitourinary toxicities in unfavorable-risk prostate cancer patients receiving docetaxel: Insights from a randomized trial.
    Cancer. 2024 Mar 1. doi: 10.1002/cncr.35274.
    

    >> Share

    
    February 2024
57. FARAJ KS, Kaufman SR, Oerline M, Herrel LA, et al
    The 340B Program and oral specialty drugs for advanced prostate cancer.
    Cancer. 2024 Feb 23. doi: 10.1002/cncr.35262.
    

    >> Share

    
    
58. RUAN Y, Heer E, Warkentin MT, Jarada TN, et al
    The association between neighborhood-level income and cancer stage at diagnosis and survival in Alberta.
    Cancer. 2024;130:563-575.
    

    >> Share

    
    
59. WRIGHT JL, Schenk JM, Gulati R, Beatty SJ, et al
    The Prostate Cancer Active Lifestyle Study (PALS): A randomized controlled trial of diet and exercise in overweight and obese men on active surveillance.
    Cancer. 2024 Feb 14. doi: 10.1002/cncr.35241.
    

    >> Share

    
    
60. LOEB S, Hua Q, Bauer SR, Kenfield SA, et al
    Plant-based diet associated with better quality of life in prostate cancer survivors.
    Cancer. 2024 Feb 13. doi: 10.1002/cncr.35172.
    

    >> Share

    
    
61. HIGANO CS, Dizdarevic S, Logue J, Richardson T, et al
    Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE).
    Cancer. 2024 Feb 10. doi: 10.1002/cncr.35221.
    

    >> Share

    
    
62. DORFF TB, Bryce AH
    Challenges in clinical trials for high-risk but curable prostate cancer.
    Cancer. 2024 Feb 10. doi: 10.1002/cncr.35245.
    

    >> Share

    
    
63. BOUE A, Joly F, Lequesne J, Lange M, et al
    Does hormone therapy impact cognition in patients with prostate cancer? A systematic review and meta-analysis.
    Cancer. 2024 Feb 2. doi: 10.1002/cncr.35210.
    

    >> Share

    
    January 2024
64. BYRD DA, Zouiouich S, Karwa S, Li XS, et al
    Associations of serum trimethylamine N-oxide and its precursors with colorectal cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial Cohort.
    Cancer. 2024 Jan 29. doi: 10.1002/cncr.35219.
    

    >> Share

    
    
65. BRAUN AE, Chan JM, Neuhaus J, Cowan JE, et al
    The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable-risk prostate cancer.
    Cancer. 2024 Jan 27. doi: 10.1002/cncr.35215.
    

    >> Share

    
    
66. XU J, Bock CH, Janisse J, Woo J, et al
    Determinants of active surveillance uptake in a diverse population-based cohort of men with low-risk prostate cancer: The Treatment Options in Prostate Cancer Study (TOPCS).
    Cancer. 2024 Jan 22. doi: 10.1002/cncr.35190.
    

    >> Share

    
    
67. MCKAY RR, Xie W, Yang X, Acosta A, et al
    Postradical prostatectomy prostate-specific antigen outcomes after 6 versus 18 months of perioperative androgen-deprivation therapy in men with localized, unfavorable intermediate-risk or high-risk prostate cancer: Results of part 2 of a randomized ph
    Cancer. 2024 Jan 1. doi: 10.1002/cncr.35170.
    

    >> Share

    
    December 2023
68. FARAJ KS, Kaufman SR, Herrel LA, Maganty A, et al
    Urologist practice divestment from radiation vault ownership and treatment patterns for prostate cancer.
    Cancer. 2023 Dec 26. doi: 10.1002/cncr.35168.
    

    >> Share

    
    
69. 
    FDA approves new combined treatment for advanced prostate cancer.
    Cancer. 2023;129:3841-3842.
    

    >> Share

    
    
70. KARAN D, Wick J, Dubey S, Kumar-Sinha C, et al
    Reply to "Contextualizing racial associations in prostate cancer to expose structural causes".
    Cancer. 2023 Dec 11. doi: 10.1002/cncr.35167.
    

    >> Share

    
    
71. ROLLIN FG, Olsen E, George M
    Contextualizing racial associations in prostate cancer to expose structural causes.
    Cancer. 2023 Dec 11. doi: 10.1002/cncr.35157.
    

    >> Share

    
    
72. GAFFNEY CD, Tin AL, Fainberg J, Fine S, et al
    The oncologic risk of magnetic resonance imaging-targeted and systematic cores in patients treated with radical prostatectomy.
    Cancer. 2023;129:3790-3796.
    

    >> Share

    
    November 2023
73. YANG K, Doege D, Thong MSY, Koch-Gallenkamp L, et al
    Diabetes mellitus in long-term survivors with colorectal, breast, or prostate cancer: Prevalence and prognosis. A population-based study.
    Cancer. 2023 Nov 23. doi: 10.1002/cncr.35133.
    

    >> Share

    
    
74. NIERENGARTEN MB
    Targeting metabolic abnormality for advanced prostate cancer: The prodrug Platin-L effectively targets the metabolic abnormality needed to make this cancer sensitive to cisplatin.
    Cancer. 2023;129:3516.
    

    >> Share

    
    
75. BRAWLEY OW, Ramalingam R
    The enigma of race and prostate cancer.
    Cancer. 2023 Nov 6. doi: 10.1002/cncr.35032.
    

    >> Share

    
    
76. LEE KM, Bryant AK, Lynch JA, Robison B, et al
    Association between prediagnostic PSA and prostate cancer probability in Black and non-Hispanic White men.
    Cancer. 2023 Nov 6. doi: 10.1002/cncr.34979.
    

    >> Share

    
    October 2023
77. NIERENGARTEN MB
    Genomics likely are not the main driver in advanced prostate cancer overall survival rate disparities.
    Cancer. 2023;129:3192.
    

    >> Share

    
    
78. LEEMAN JE, Shin KY, Chen YH, Mak RH, et al
    Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: A systematic review and meta-analysis.
    Cancer. 2023;129:3044-3052.
    

    >> Share

    
    September 2023
79. KARAN D, Wick J, Dubey S, Kumar-Sinha C, et al
    Racial differences in serum chemokines in prostate cancer patients.
    Cancer. 2023 Sep 12. doi: 10.1002/cncr.35012.
    

    >> Share

    
    August 2023
80. ISLAMI F, Wiese D, Marlow EC, Kratzer TB, et al
    Progress in reducing cancer mortality in the United States by congressional district, 1996-2003 to 2012-2020.
    Cancer. 2023;129:2522-2531.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share